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Utilization of osmotic pressure as a driving force for delivery of pharmaceutical
agents in a controlled pattern for a prolonged period of time is a well-established fact.
The concept of osmotic drug delivery was first introduced by Theeuwes (1). The sim-
plest design of an osmotic drug delivery system consists of an osmotically active core
surrounded by a semipermeable membrane, with one or more delivery orifices through
which the drug is delivered in a controlled fashion. Various modifications of the basic
design of osmotic pump have been reported (2) and reviewed (3, 4).
One such modification is the utilization of asymmetric membrane coating for os-
motic drug delivery. The walls of an asymmetric membrane capsule are prepared by the
phase inversion technique. As the name suggests, the membrane is asymmetric in na-
ture, i.e., it has a relatively thin dense region supported on a thicker porous region (5).
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An asymmetric membrane capsule of cellulose acetate for
osmotic delivery of flurbiprofen has been developed and
influence of osmogents and solubilizing agent on in vitro
drug release were evaluated. The capsule membrane was
prepared by the phase inversion technique. To ensure the
osmotic delivery of drug, two approaches were adopted:
(i) the drug was encapsulated with osmogents like sodium
chloride and mannitol to increase the osmotic pressure
of the core, and (ii) the drug was encapsulated with so-
dium lauryl sulfate in the core of the formulation to in-
crease the solubility and thus its osmotic pressure. Scan-
ning electron microscopy of the membrane confirmed its
porous, dense asymmetric nature. Dye test revealed in
situ pore formation. The in vitro release study showed
that as the proportion of osmogent and solubilizing
agent was increased the release rate also increased. A
good correlation was observed between the zero-order
rate constant and the amount of the osmogent and solu-
bilizing agent used.
Keywords: osmotic delivery, asymmetric membrane, cel-
lulose acetate, flurbiprofen, osmogent
* Correspondence, e-mail: chetansinghchauhan2k@rediffmail.com
Asymmetric membrane capsule consists of a cap and a body, which fit snugly. The wall
of the asymmetric membrane capsule is made from a water-insoluble polymer like cellu-
lose acetate, ethyl cellulose, cellulose acetate butyrate or their mixture, thus the capsule
shell of the asymmetric membrane, unlike the gelatin capsule, does not dissolve instan-
taneously and osmotically delivers the drug for a prolonged period of time, depending
upon the core composition (6).
The critical difference between the asymmetric membrane osmotic dosage form and
other osmotic devices is a higher rate of water influx due to the micro porous nature of
the asymmetric membrane. It aids in delivery of a drug with lower osmotic pressure and
solubility (7). For drugs of poor solubility, high water influx is desirable, which can be
easily achieved with the asymmetric membrane by proper choice and concentration of
the pore forming agent. Further, the solubility of the poorly water-soluble drug inside
the core can be increased by encapsulating the drug with osmogents or solubilizing agent
to ensure its osmotic delivery (8).
Unlike other osmotic systems where a delivery orifice is required in the semiper-
meable membrane for delivery of the drug, the asymmetric membrane coating provides
a distinct advantage of in situ pore formation. The in situ pore formation takes place due
to leaching of the water-soluble additives incorporated in the asymmetric membrane. The
leaching of water-soluble additives takes place when such a system comes in contact
with the aqueous medium, resulting in formation of a micro porous membrane, through
which the drug is osmotically delivered (9). This membrane is permeable to both water
and dissolved solute, economically viable, less time consuming compared to a mechani-
cal drill or laser drilling. Drug release from this system is to a large extent independent
of pH and other physiological factors (10).
In our previous study (11), influence of the asymmetric membrane porosity on the
release of poorly water-soluble drugs was investigated. The release rates were found to
significantly increase with an increase in concentration of the pore forming agent in the
asymmetric membrane. In the present study, the effect of osmogents (sodium chloride,
mannitol) and solubilizing agent (sodium lauryl sulfate, SLS) on the osmotic release of
the poorly water-soluble drug flurbiprofen (FL) from the asymmetric membrane capsule
of cellulose acetate has been investigated.
EXPERIMENTAL
Cellulose acetate was obtained from Glaxo Lab. Ltd. (India), sodium lauryl sulfate,
sodium chloride and mannitol were obtained from S.D. Fine Chemicals Ltd. (India); the
drug flurbiprofen was a gift sample from FDC Pharmaceutical Ltd. (India).
Asymmetric membrane capsule preparation
Cellulose acetate (CA) solution (15% m/V) was prepared in an acetone/water (90/10,
V/V) solvent system. Accurately weighed quantity of CA was added to acetone/water
and the resulting mixture was stirred in a well-closed beaker to obtain a solution. The re-
quired quantity of the pore forming agent glycerol (10 g) was added to the solution un-
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der stirring. The stainless steel moulds dimensioned so as to form the capsule body and
cap were dipped in the coating solution for 2 minutes and then removed carefully so as
to form a thin layer of solution on the mould. The pins were taken out of the coating so-
lution and briefly air dried for 30 seconds, followed by quenching in aqueous solution
(10%, m/V, glycerol) to effect phase inversion and formation of the asymmetric mem-
brane. The resulting membrane was stripped off and trimmed to desired size and stored
for future use. The porosity and structure of the asymmetric membrane were character-
ized by scanning electron microscopy (SEM) (LEO-340, Lyca Electron Optics, UK).
Filling and sealing of the asymmetric membrane capsule
The asymmetric membrane capsule was filled with a mixture of drug/osmogent
(sodium chloride, mannitol) and drug/solubilizing agent (SLS) each in the ratio of 1:1,
1:5 and 1:10 (m/m), keeping the drug quantity constant (100 mg). One such capsule was
filled with pure drug, 100 mg, without any osmogent or solubilizing agent; this capsule
served as control. Each of the mixtures was filled in the body of the capsule and the cap
was snuggly fitted to the body and finally sealed with a 16% (m/V) solution of CA, only
so as to ensure that no release took place through the seal of the capsule. The physical
mixtures of drug/osmogent and drug/solubilizing agent were prepared by mixing
them thoroughly in a laboratory blender for 10 minutes and subsequently passing the
mixture through sieve No. 80 (aperture size 180 mm, US Standard).
Osmotic release study
The prepared asymmetric membrane capsules of cellulose acetate were character-
ized for osmotic release behaviour by conducting a dye-test. For this purpose, capsules
were filled with the water-soluble dye amaranth (12), mixture of dye with osmogent (so-
dium chloride) and solubilizing agent SLS. The capsules were then suspended separa-
tely in 50 mL water and 50 mL sodium chloride solution (10%, m/V). The capsules were
observed visually for release of any coloured dye.
Release rate study
The in vitro study of drug release from each capsule was studied as the function of
the increasing amount of added osmogent and solubilizing agent in each system. The
filled capsules were subjected to a release rate study using a USP 24 (13) dissolution ap-
paratus II (50 rpm, 37± 0.5 °C) and phosphate buffer pH 7.2 as dissolution medium. The
samples were withdrawn hourly for nine hours and analyzed using a UV spectropho-
tometer (UV/VIS-1 Spectrophotometer, Thermo Spectronic, UK) at 247 nm. The experi-
ments were performed in triplicate.
Statistical analysis
Experimental results were expressed as mean ± SD values. Student’s t test was per-
formed to determine the level of significance between the control capsule and the cap-
sule filled with various proportions of osmogents and solubilizing agent. Two-way analysis
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of variance was used to assess the difference in release rate from the capsules filled with
different types of osmogent and proportions of osmogents and solubilizing agent. Dif-
ferences were considered to be statistically significant at p < 0.05.
RESULTS AND DISCUSSION
A stream of dye was observed diffusing from the capsule suspended in distilled wa-
ter after a lag time of 36 minutes, suggesting in situ pore formation that acts as a delivery
port for release of the colored dye. However, no stream of dye was observed when an-
other such capsule was placed in 10% (m/V) solution of sodium chloride. This was due
to high osmotic pressure of the release medium, which nullifies the osmotic release of
the encapsulated dye, suggesting that the prepared system follows the osmotic principle
for releasing encapsulated materials. But when the capsules were filled with a mixture
of dye/osmogent (sodium chloride) and dye/solubilizing agent (SLS), a reduction in lag
time was observed due to the increase in the osmotic pressure inside the system. The de-
crease in lag time may be due to the increase in the osmotic pressure inside the system
causing early release of the dye. This concept was utilized in the present study to ensure
the osmotic delivery of (FL) by increasing the osmotic pressure of the core. The SEM of
the asymmetric membrane (Fig. 1) indicates the presence of a porous region at 60 magni-
fication confirming the porous and asymmetric nature of the membrane.
The in vitro drug release study from the asymmetric membrane capsule filled with
various ratios of osmogents (sodium chloride and mannitol) and solubilizing agent SLS
is shown in Fig. 2. and indicates that as the proportion of osmogent and solubilizing
agent is increased, the amount of drug released also increases (Table I). However, the
amount of drug released at the end of the dissolution run from the control capsule was
significantly lower as compared to capsules filled with various proportions of drug/
osmogent (sodium chloride, mannitol) and drug/SLS (Table I). The findings of two-way
ANOVA at 5% level of significance reveal that those is a significant difference in drug re-
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Fig. 1. Cross-section of the asymmet-
ric membrane at 60x magnification.
lease between different types of osmogents and osmogent and solubilizing agent as well
as their proportions (between ratios F = 19.85, between NaCl, manitol and SLS F = 7.55;
see Table I).
Influence of osmogents and solubilizing agent
Though osmotic pressure of sodium chloride is higher compared to mannitol (14),
higher release rates were observed with drug/mannitol combination. The lower release
rate from the system with sodium chloride can be attributed to its ionic nature and high
osmolarity. Both these factors would lead to rapid ionization of sodium chloride com-
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Table I. Maximum flurbiprofen released from the asymmetric membrane capsule
Ratio (m/m)a
Maximum FL released (%)b
Control NaCl Mannitol SLS
FL only (100 g) 5.6 ± 0.5 – – –
1:1 – 11.3 ± 1.0c 16.4 ± 1.1c 21.0 ± 1.3c
1:5 – 28.3 ± 1.1c 36.4 ± 1.0c 48.3 ± 1.1c
1:10 – 35.8 ± 0.9c 48.2 ± 1.1c 72.4 ± 1.1c
a FL: Osmogent/solubilizing agent ratio (m/m).
b Mean ± SD (n = 3).































Fig. 2. Release profile of flurbiprofen from the asymmetric membrane capsule filled with various
ratios of: FL/NaCl: 1:1 (), 1:5 (), 1:10 (); FL/mannitol: 1:1 (), 1:5 (), 1:10 (); FL/SLS: 1:1
(), 1:5 (×), 1:10 (—). Each point represents mean ± SD value (n = 3).
pared to (FL) and suppress its ionization due to the common ion effect, and also com-
pete with the drug to get released from the system. This would reduce residence time of
sodium chloride in the system necessary to impart the osmotic pressure required to ef-
fect substantial release of the drug from the system.
The higher release rates from the system with mannitol can be attributed to its non-
-ionic nature and low osmolarity. The phenomenon of competing with the drug to get
released from the system and suppression of drug ionization due to the common ion ef-
fect will not occur in the case of mannitol. Hence mannitol would have extended resi-
dence time in the system, required to impart the necessary osmotic pressure to cause
prolonged drug release from the system.
Higher release rates were observed from the systems with the solubilizing agent,
SLS, compared to systems filled with osmogent (sodium chloride, mannitol). This may
be due to the solubilization effect of SLS causing increased solubility of the drug, incre-
asing the osmotic pressure of the drug itself, resulting in an increased amount of drug
being released from the system. It appears that SLS, besides imparting, solubilization ef-
fect, also acts as an osmogent in dissolved form.
The correlation coefficient of the linear relationship between the percent cumulative
drug released and the in vitro release time suggests that the system follows zero-order
release irrespective of the proportion of the drug/osmogent and drug/solubilizing
agent encapsulated in the system (Table II).
The amount of the drug released from each system does depend upon the amount of
osmogent and solubilizing agent encapsulated along with the drug, as evident from the
zero-order release rate constants (Table II). The correlation coefficient between the zero-or-
der release rate constant and the amount of osmogent and solubilizing agent was found to
be 0.918 for sodium chloride, 0.967 for mannitol and 0.994 for SLS. The good linear rela-
tionship in the case of mannitol and SLS suggests that the amount of mannitol and SLS re-
quired to achieve 100% release of drug can be predicted from the regression equation.
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Table II. Kinetics of in vitro release of flurbiprofen from the asymmetric membrane capsule
Ratio (m/m)a
Zero-order
R2 k0 (mg h–1)
FL/NaCl (1:1) 0.966 1.223
FL/NaCl (1:5) 0.987 3.423
FL/NaCl (1:10) 0.983 4.372
FL/mannitol (1:1) 0.975 1.891
FL/mannitol (1:5) 0.976 4.283
FL/mannitol (1:10) 0.988 5.674
FL/SLS (1:1) 0.984 2.532
FL/SLS (1:5) 0.995 5.678
FL/SLS (1:10) 0.992 8.720
a Flurbiprofen/osmogent or flurbiprofen/solubilizing agent ratio.
k0 – Zero-order rate constant.
CONCLUSIONS
This study suggests that drug delivery from the asymmetric membrane capsule is
principally controlled by the osmotic pressure of the core formulation. The in situ form-
ed delivery orifice in the asymmetric membrane is mainly responsible for drug delivery.
Solubilization of a poorly water-soluble drug in the core increases its release rate and the
amount of drug released.
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S A @ E T A K
Kapsule s asimetri~nom membranom za osmotsku isporuku flurbiprofena
PRATIM K. CHOUDHURY, MAHENDRA S. RANAWAT, MOUSUMI K. PILLAI i CHETAN S. CHAUHAN
U radu je opisan razvoj kapsula s asimetri~nom membranom od celuloznog acetata
za osmotsku isporuku flurbiprofena. Prou~avan je utjecaj osmotski-aktivnih tvari i tvari
za pove}anje topljivosti na osloba|anje ljekovite tvari in vitro. Membrane kapsula su pri-
re|ene metodom inverzne faze. Osmotska isporuka je osigurana na dva na~ina. Ljeko-
vita tvar je kapsulirana s: i) osmotski-aktivnim tvarima poput natrijeva klorida i manitola
koji su pove}ali osmotski tlak jezgre, ii) natrijevim lauril-sulfatom koji je pove}ao top-
ljivost te ujedno i osmotski tlak. Pretra`na elektronska mikroskopija ukazuje na poroznu
membranu asimetri~ne gusto}e, a test boje na stvaranje pora in situ. In vitro pokusi su
pokazali da osloba|anje ljekovite tvari iz kapsula raste s pove}anjem koli~ine osmotski-
-aktivnih tvari i tvari za pove}anje topljivosti te da postoji dobra korelacija izme|u
upotrebljene koli~ine tih tvari i konstante osloba|anja nultog reda.
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